{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:38:10Z","timestamp":1761896290858},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Irving Hansen Foundation"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.leukres.2016.04.015","type":"journal-article","created":{"date-parts":[[2016,5,2]],"date-time":"2016-05-02T05:30:22Z","timestamp":1462167022000},"page":"74-78","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients"],"prefix":"10.1016","volume":"46","author":[{"given":"Karen","family":"Seiter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasir","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azfar","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Baskind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"October (14)","key":"10.1016\/j.leukres.2016.04.015_bib0005","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B","volume":"331","author":"Mayer","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"September (1\u20132)","key":"10.1016\/j.leukres.2016.04.015_bib0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428190009053545","article-title":"Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia","volume":"39","author":"Robak","year":"2000","journal-title":"Leuk. Lymphoma"},{"issue":"March (3)","key":"10.1016\/j.leukres.2016.04.015_bib0015","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.1992.10.3.364","article-title":"B. lakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia","volume":"10","author":"Santana","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"January (1)","key":"10.1016\/j.leukres.2016.04.015_bib0020","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V87.1.256.256","article-title":"Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions","volume":"87","author":"Gandhi","year":"1996","journal-title":"Blood"},{"issue":"December (12)","key":"10.1016\/j.leukres.2016.04.015_bib0025","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0145-2126(98)00117-9","article-title":"Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia","volume":"22","author":"Ohno","year":"1998","journal-title":"Leuk. Res."},{"issue":"September (3)","key":"10.1016\/j.leukres.2016.04.015_bib0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1034\/j.1600-0609.2003.00122.x","volume":"71","author":"Wrzesie\u0144-Ku\u015b","year":"2003","journal-title":"Eur. J. Haematol."},{"issue":"September (9)","key":"10.1016\/j.leukres.2016.04.015_bib0035","first-page":"557","volume":"84","author":"Wrzesie\u0144-Ku\u015b","year":"2005","journal-title":"Ann. Hematol."},{"issue":"September (13)","key":"10.1016\/j.leukres.2016.04.015_bib0040","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"September (13)","key":"10.1016\/j.leukres.2016.04.015_bib0045","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"April (7)","key":"10.1016\/j.leukres.2016.04.015_bib0050","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/cncr.25598","article-title":"Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome","volume":"117","author":"Bello","year":"2011","journal-title":"Cancer"},{"issue":"February (7)","key":"10.1016\/j.leukres.2016.04.015_bib0055","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"issue":"March (3)","key":"10.1016\/j.leukres.2016.04.015_bib0060","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.leukres.2010.09.002","article-title":"Salvage chemotherapy regimens for acute myeloid leukemia: is one better? Efficacy comparison between CLAG and MEC regimens","volume":"35","author":"Price","year":"2011","journal-title":"Leuk. Res."},{"issue":"April (4)","key":"10.1016\/j.leukres.2016.04.015_bib0065","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.leukres.2013.12.010","article-title":"Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure","volume":"38","author":"Jaglal","year":"2014","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.leukres.2016.04.015_bib0070","article-title":"Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study","volume":"30","author":"Holowiecki","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"May (10)","key":"10.1016\/j.leukres.2016.04.015_bib0075","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","article-title":"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)","volume":"107","author":"Thiede","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2016.04.015_bib0080","doi-asserted-by":"crossref","first-page":"e109759","DOI":"10.1371\/journal.pone.0109759","article-title":"The NPM1 mutation type has no impact on survival in cytogenetically normal AML","volume":"9","author":"Pastore","year":"2014","journal-title":"PLoS One"},{"issue":"May (15)","key":"10.1016\/j.leukres.2016.04.015_bib0085","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1200\/JCO.2013.52.3480","article-title":"Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia","volume":"32","author":"Pastore","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T05:56:56Z","timestamp":1600495016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616300698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":17,"alternative-id":["S0145212616300698"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.04.015","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}